- Home
- CABA vs ACRE Comparison
CABA vs ACRE Comparison
Compare CABA & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- ACRE
- Stock Information
- Founded
- CABA 2017
- ACRE 2011
- Country
- CABA United States
- ACRE United States
- Employees
- CABA N/A
- ACRE N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- ACRE Real Estate Investment Trusts
- Sector
- CABA Health Care
- ACRE Real Estate
- Exchange
- CABA Nasdaq
- ACRE Nasdaq
- Market Cap
- CABA 233.2M
- ACRE 254.1M
- IPO Year
- CABA 2019
- ACRE 2012
- Fundamental
- Price
- CABA $2.32
- ACRE $4.91
- Analyst Decision
- CABA Strong Buy
- ACRE Hold
- Analyst Count
- CABA 8
- ACRE 5
- Target Price
- CABA $13.50
- ACRE $5.08
- AVG Volume (30 Days)
- CABA 5.3M
- ACRE 432.9K
- Earning Date
- CABA 11-10-2025
- ACRE 11-07-2025
- Dividend Yield
- CABA N/A
- ACRE 12.17%
- EPS Growth
- CABA N/A
- ACRE N/A
- EPS
- CABA N/A
- ACRE N/A
- Revenue
- CABA N/A
- ACRE $87,777,000.00
- Revenue This Year
- CABA N/A
- ACRE N/A
- Revenue Next Year
- CABA N/A
- ACRE N/A
- P/E Ratio
- CABA N/A
- ACRE N/A
- Revenue Growth
- CABA N/A
- ACRE 122.65
- 52 Week Low
- CABA $0.99
- ACRE $3.35
- 52 Week High
- CABA $5.46
- ACRE $7.49
- Technical
- Relative Strength Index (RSI)
- CABA 44.66
- ACRE 59.07
- Support Level
- CABA $2.30
- ACRE $4.33
- Resistance Level
- CABA $2.67
- ACRE $4.98
- Average True Range (ATR)
- CABA 0.33
- ACRE 0.18
- MACD
- CABA -0.07
- ACRE 0.05
- Stochastic Oscillator
- CABA 8.05
- ACRE 78.95
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.